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HIV-1-associated dementia (HAD)-relevant proinﬂammatory cytokines robustly induce astrocyte tissue inhibitor of
metalloproteinases-1 (TIMP-1). As TIMP-1 displays pleotropic functions, we hypothesized that TIMP-1 expression may serve
as a neuroprotective response of astrocytes. Previously, we reported that chronically activated astrocytes fail to maintain
elevated TIMP-1 expression, and TIMP-1 levels are lower in the brain of HAD patients; a phenomenon that may contribute to
central nervous system pathogenesis. Further, the role of TIMP-1 as a neurotrophic factor is incompletely understood. In this
study, we report that staurosporine (STS) and HIV-1ADA virus, both led to induction of apoptosis in cultured primary human
neurons. Interestingly,cotreatment with TIMP-1 protects neurons from apoptosis and reverses neuronal morphological changes
induced by these toxins.Further, the anti-apoptotic effect was notobservedwithTIMP-2or -3,butwas retainedina mutant of the
N-terminal TIMP-1 protein with threonine-2 mutated to glycine (T2G) that is deﬁcient in matrix metalloproteinase (MMP)-1, -2
and -3 inhibitory activity. Therefore, the mechanism is speciﬁc to TIMP-1 and partially independent of MMP-inhibition.
Additionally, TIMP-1 modulates the Bcl-2 family of proteins and inhibits opening of mitochondrial permeability transition pores
induced by HIV-1 or STS. Together, these ﬁndings describe a novel function, mechanism and direct role of TIMP-1 in
neuroprotection, suggesting its therapeutic potential in HAD and possibly in other neurodegenerative diseases.
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The tissue inhibitors of metalloproteinases (TIMP) family are
composed of four members (TIMP-1, 2, 3, and 4), which, by
deﬁnition, inhibit the activity of matrix metalloproteinases
(MMP), a large family of zinc-dependent proteases. The
TIMP/MMP balance is crucial in extracellular matrix (ECM)
homeostasis and remodeling; which is essential for diverse
physiological processes including cell growth, migration and
apoptosis in a variety of cells.
1 The MMP/TIMP imbalance is
mechanistically implicated in several central nervous system
(CNS) and neurodegenerative diseases, including ischemia,
Alzheimer’s disease and neuroinﬂammatory diseases like
human immunodeﬁciency virus (HIV)-1-associated dementia
(HAD).
2 As each TIMP can inhibit a wide spectrum of MMPs,
TIMPs affect many cellular functions such as growth,
migration, and apoptosis. However, it is now strongly evident
by the identiﬁcation of speciﬁc binding partners on cells that
these cellular activities of TIMPs may or may not require
MMP-inhibitory activity.
1
In the CNS, TIMP-1 expression increases signiﬁcantly
during postnatal development as compared with adult, but
TIMP-1 is currently studied with particular interest in disease
process because of its robust overexpression in response to
inﬂammatory myelin injury.
3 As TIMP-1 is predominantly
expressed by astrocytes surrounding white matter lesions, it
likely acts as an endogenous factor to rescue cells from the
toxic effects of MMP activities during neuroinﬂammation.
4
However, besides the classical function of MMP-inhibition,
TIMP-1 also possesses growth factor activity and anti-
apoptotic potential; which may be mediated through ligand–
receptor interactions.
5–7 Hence, TIMP-1 biological functions
are not limited to MMP-inhibition, but may include develop-
ment, CNS injury, and inﬂammation.
8
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www.nature.com/cddisWe and other laboratories have previously reported that
astrocytes increase the production of TIMP-1 in response to
proinﬂammatory cytokines, such as interleukin (IL)-1b and/or
tumor necrosis factora indicating a role of TIMP-1 in
neuroinﬂammation.
8,9 Astrocytic TIMP-1 expression in
response to pro-inﬂammatory cytokines is substantial
because astrocytes, not microglia, upregulate TIMP-1 levels
upon activation with IL-1b.
10 Previously, we have shown that,
in contrast to acute inﬂammation, TIMP-1 levels decrease
during chronic inﬂammation in vitro, as well as in cerebro-
spinal ﬂuid (CSF) and brain tissue of HAD patients.
9 These
data indicate that the initial robust injury-induced astrocyte
TIMP-1 expression may serve to protect from neuronal
damageattheinﬂammatoryfoci.Interestingly,TIMP-1inhibits
excitotoxic cell death in neuronal cells in animal models, likely
through the modulation of intracellular calcium levels, but
speciﬁc mechanistic studies in context of human targets and
HAD are lacking.
11 The analysis of brain tissues from HAD-
patients, animal and cell culture models of the disease
strongly indicated that apoptosis was a predominant con-
tributor to neuronal death in HIV-1 CNS infection.
12 In these
studies, neuronal apoptosis was characterized morphologi-
cally by decrease in cell volume, bleb-like cell surface
protuberances, chromatin condensation and DNA fragmenta-
tion. However, the exact mechanism(s) of HIV-1-induced
neuronal apoptosis remains unknown. Understanding the
mechanisms operating in the CNS to protect neurons from
toxicity by HIV-1 is critical from a clinical perspective and for
developing rational therapies that can prevent neuronal death
after injury or long-term disease. These factors led us to
hypothesize that TIMP-1 may have a neuroprotective role in
CNS during HAD. There are multiple pathways and mechan-
isms that may be responsible for HIV-1-induced apoptosis in
neurons; therefore, a broad-spectrum apoptosis-inducing
agent should be used in order to study TIMP-1 neuroprotec-
tive effects.
Herein, we report the neuroprotective potential of TIMP-1 in
cultured primary human neurons against HIV-1 and stauro-
sporine(STS),a modelcytotoxinextensively usedtodecipher
the underlying mechanisms of apoptosis.
13 Our results
demonstrate that TIMP-1-mediated neuroprotection is MMP-
independent, at least in part, through modulation of Bcl-2
family of proteins, decreasing of the opening of mitochon-
drial membrane permeability transition pore (mPTP) and
eventually preventing DNA fragmentation. Results from this
study identify TIMP-1 as a novel astrocyte-derived factor that
can directly inﬂuence neuronal survival during HIV-1-asso-
ciated neurotoxicity.
Results
TIMP-1 protects human neurons against STS-induced
toxicity. We ﬁrst examined the effect of TIMP-1 on human
neuronal survival during STS-induction of apoptosis. STS-
treatment signiﬁcantly increased the percentage of terminal
deoxynucleotidyltransferase-mediated dUTP-nick end label-
ing (TUNEL)-positive neuronal nuclei (B35%, Po0.001;
Figures 1d and g), which was signiﬁcantly reduced upon
TIMP-1 cotreatment (B50%, Po0.001; Figures 1e and g).
As previously reported,
14 brain-derived neurotrophic factor
(BDNF) also signiﬁcantly reduced percent apoptotic nuclei in
STS-challenged neurons (Po0.001; Figures 1f and g).
Moreover, TIMP-1-treatment alone improved the morphology
of neurons (Figures 1b and g) and decreased basal
apoptosis signiﬁcantly as compared with untreated control
(Po0.001; Figures 1g and i). This could be due to an innate
neurotrophic activity of TIMP-1. Cotreatment of the neurons
with STS and either TIMP-1 or BDNF signiﬁcantly improved
the metabolic activity in neurons (Figure 1h; Po0.01 and
Po0.05, respectively). STSþTIMP-1 and STSþBDNF
groups were not statistically different, indicating that TIMP-1
is comparable to BDNF in its ability to protect neurons
against STS-induced neurotoxicity. In parallel experiments,
we determined TIMP-1 neuroprotection by quantitatively
measuring double-strand DNA fragments by double-stranded
DNA fragmentation enzyme-linked immunosorbant assay
(dsDNA ELISA). STS induced a dose-dependent increase in
DNA fragmentation in human neurons (Po0.001, Figure 1i),
which was decreased signiﬁcantly upon TIMP-1-treatment as
compared with the same dose of STS-alone (Po0.001,
Figure 1i). These observations suggest that TIMP-1 is a
pro-survival and anti-apoptotic factor for neurons and
contributes to the suppression of apoptosis induced by
STS in human neurons.
Neuroprotection is speciﬁc to TIMP-1 and likely inde-
pendent of MMP inhibition. As TIMPs have divergent
effects on proliferation and apoptosis independent of their
MMP-activity in a number of cell types, we next investigated
if TIMP-1 protects neurons because of its intrinsic property of
MMP-inhibition.
1 By using a N-terminal TIMP-1 protein with
threonine-2 mutated to glycine (T2G) which differs from the
wild-type protein by a single-amino-acid substitution, and
reduces the inhibition constant of TIMP-1 for MMP-1 and
MMP-3 by a factor of over 1000 and an B20-fold effect on
MMP-9.
15,16 Moreover, the secondary structure of this
mutant protein is not signiﬁcantly different than wild type.
Therefore, any neuroprotective effect of T2G treatment is
MMP-independent.
17
Neuronal cultures were treated with STS and the morpho-
logical changes were visualized by immunocytochemical
staining for microtubule-associated protein (MAP)-2, neuron
speciﬁc marker. The characteristic morphological changes
due to apoptosis were observed in STS-challenged neurons,
viz. signiﬁcant loss of 4’,6-diamidino-2-phenylindole (DAPI)-
stained nuclei and MAP-2-positive cells (Figure 2b). Further-
more, shrunken cell bodies with beading, fragmented, or
obliterated neuronal processes were observed in remaining
STS-treated MAP-2-positive neurons conﬁrming the cytotoxic
effects of STS on neuronal morphology and survival.
Cotreatment of neurons with STS and either TIMP-1, T2G
mutant or BDNF considerably prevented STS-induced cell
deathcompared with STS alone, and STS in combination with
BSA (bovine serum albumin, negative control) (Figures 2a
and c–f). Moreover, cotreatment with TIMP-1, T2G and
BDNF also prevented impairments in morphology, integrity
of cell body, as well as neurite network and processes.
Furthermore, neuroprotection by the T2G mutant was
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3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay as a measure of metabolic activity (Figure 2g).
Based upon these studies, TIMP-1-mediated neuroprotection
appears to be independent of its MMP-inhibition activity.
As, the TIMP family members exhibit promiscuity in their
MMP-inhibition activity, we determined whether the neuro-
protective functions of TIMP-1 are shared by TIMP-2 and -3,
each of which binds and inhibits MMP activity. TIMP-2 binds
pro-MMP-9, and was speciﬁcally included to determine if
MMP-9 inhibition has a role in TIMP-1 neuroprotection, as the
T2G mutant had reduced but continued MMP-9 inhibiting
capacity. As observed by the above-mentioned assays, STS
signiﬁcantly increased the neuronal death as measured by
trypan-blue exclusion assay (Figures 2b and g; Po0.001).
TIMP-1 and T2G mutant both signiﬁcantly decreased the
percentage of apoptotic cells (Figures 3c, d, and g; Po0.01,
respectively). However, TIMP-2 and TIMP-3, which
have MMP-inhibiting activities, did not display signiﬁcant
neuroprotective effects as compared with STS-alone
(Figures 3e–g; P40.05). Thus, these results strongly suggest
that TIMP-1-mediated neuroprotection is speciﬁc and MMP-
independent.
TIMP-1 mediates neuroprotection against HIV-1ADA
virus. We next evaluated the relevance of neuroprotective
potential of TIMP-1 in HAD by treating neurons with
macrophage-tropic HIV-1ADA viral particles, with or without
TIMP-1 cotreatment. TIMP-1 ameliorated the degradation in
neuronal morphology, shrinkage of cell bodies and fragmen-
tation of neuronal processes exerted by HIV-1ADA on human
neurons (Figures 4c and d). TIMP-1-cotreatment signiﬁcantly
reduced apoptosis (B20%, Po0.001) as compared with
HIV-1ADA-alone neurons (B80%, Figures 4c and e;
Po0.001) as determined by TUNEL-assay. Taken together,
these results conﬁrmed TIMP-1 neuroprotection as evident
by decreased apoptosis and preservation of cellular
morphology in the presence of HAD-speciﬁc neurotoxin,
HIV-1ADA.
TIMP-1 inhibits mPTP opening. The opening of mPTP is
an early apoptotic event in neurons and represents the ‘point
Figure 1 TIMP-1 enhances neuronal survival against STS-cytotoxicity. Primary human neurons were treated with STS with or without 50ng/ml of TIMP-1 or BDNF for
24h. The cells were ﬁxed and stained (a–f) with TUNEL and DAPI (nuclei with fragmented DNA stained black, arrowhead; while nuclei with intact DNA stained blue, arrow).
Percentage of apoptotic nuclei in all cells counted in a total of eighteen random microscope ﬁelds from three replicates were calculated (g). A dose-dependent effect of STS
andTIMP-1-mediatedneuroprotectionwasmeasuredbycellviabilityassay(h)andquantitativeanalysisofapoptosisbydsDNAELISA(i).Datarepresentativeofatleastthree
independentbiologicalreplicatesareshownandpresentedasmean±S.E.M.Symbolscenteredovertheerrorbarindicatetherelativelevelofthesigniﬁcancecomparedwith
untreated control (***Po0.001), STS-alone (
xPo0.05,
xxPo0.01 and
xxxPo0.001) or comparisons between TIMP-1 doses (
fffPo0.001) or between STS doses
(
cccPo0.001)
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18 As TIMP-1 protects
human neurons from STS and HIV-1ADA insult in an MMP-
independent manner, we studied whether TIMP-1 can inhibit
mPTP opening in HIV-1 or toxin challenged neurons by
acetomethoxy derivate of calcein (calcein-AM) and cobalt
chloride (CoCl2) assay. Calcein (green) colocalization in
mitochondria with MitoTraker (Life Technologies, Carlsbad,
CA, USA) (red) is visualized as a yellow ﬂuorescence. The
green/yellow ﬂuorescence is lost upon calcein release from
mitochondria consequent to mPTP opening and subsequent
quenching of ﬂuorescence by cobalt in cytoplasm. HIV-1ADA
viral particles or STS induced opening of mPTP in neurons
as depicted by loss of green/yellow ﬂuorescence (Figure 5).
However, cotreatment of TIMP-1 inhibited mPTP opening as
observed by the preservation of green/yellow ﬂuorescence
baseline levels. Moreover, HIV-1ADA- or STS-treatment alone
signiﬁcantly decreased the number of live, green ﬂuorescent
cells (as detected only by nuclear stain), as only live cells can
take up calcein-AM and metabolize it into the green
ﬂuorescent product (calcein). TIMP-1 cotreatment preserved
the number of green ﬂuorescent cells, indicating overall
cellular protection in neurons. Together, the data demon-
strate that the improved cell viability and decreased
apoptosis mediated by TIMP-1 were accompanied by
inhibition of mPTP opening.
Figure 2 TIMP-1 prevents the morphological and metabolic changes induced
by STS. Human neurons challenged with STS (0.3mM) for 24 h, with or without
50ng/ml BDNF, TIMP-1, TIMP-2 or 28ng/ml T2G mutant were assessed for
morphological changes and/or preservation/protection by immunocytochemistry
(a–f) and cell viability by MTT assay (g). Representative micrographs of
immunoﬂuorescent staining (red: MAP-2, neuronal marker, speciﬁc cytoskeletal
proteins that are enriched in dendrites and essential to stabilize its shape; green:
GFAP for astrocytes; blue: DAPI for nuclei). Arrows represent the MAP-2 enriched
neurons with DAPI and processes, while arrowheads represent loss of MAP-2,
DAPI and processes. Images are representative of ﬁve random ﬁelds (original
magniﬁcation 200) in each replicate, three replicates per condition. Data
represents at least three independent biological replicates and presented as
mean±S.E.M.Symbolscenteredover theerror bar indicatetherelativelevel of the
signiﬁcance compared with untreated control (***Po0.001) or STS-alone
(
xxxPo0.001)
Figure 3 TIMP-1-mediated neuroprotection is speciﬁc to TIMP-1 and MMP-
independent. The cell viability assay was performed in human neurons after
exposure of STS (0.3mM) for 18h with or without 50ng/ml of TIMP-1, -2, -3 or
28ng/ml T2G. Panels are representative micrographs of 10 random ﬁelds (original
magniﬁcation  200) from two replicates of control (a), STS (b) and STS with
TIMP-1 (c), T2G (d), TIMP-2 (e) or TIMP-3 (f). Trypan-blue positive cells were
considered as dead cell (represented by arrowhead) while, cells that excluded
trypan-blue were counted as live (represented by arrow) and percentage of trypan-
blue positive cells was calculated (g). Data is representative of at least three
independent biological replicates and presented as mean±S.E.M. Symbols
centered over the error bar indicate the relative level of the signiﬁcance compared
with untreated control (**Po0.01 and ***Po0.001) or STS-alone (
xxPo0.01)
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Cell Death and DiseaseTIMP-1 modulates Bcl-2 family of proteins for neuropro-
tection. The fate of the cell is determined in a large measure
by the balance of pro-apoptotic and anti-apoptotic proteins;
therefore, we studied the effect of TIMP-1 on modulation
of Bcl-2 family of proteins. The Bcl-2 family of proteins,
including Bcl-2, Bcl-xL and Bax are pivotal regulators of
intrinsic apoptotic signaling and regulate mPTP opening.
Bcl-2 and Bcl-xL exert their effects by contributing to the
maintenance of mitochondrial membrane integrity. In con-
trast, Bax compromises membrane integrity leading to
mPTP opening and leakage of apoptotic factors, such as
cytochrome c and apoptosis-inducing factor.
19,20 A robust
increase in Bax (2.84±0.02-fold) and decrease Bcl-2 and
Bcl-xL levels (approximately two-fold) were observed by
STS-treatment (Figure 6), consistent with studies performed
on rat neurons and neuroblastoma cells.
13,21 STS dramati-
cally increased the ratios of Bax/Bcl-2 and Bax/Bcl-xL by
6.22±0.12- and 6.25±0.28-fold, respectively. Interestingly,
both TIMP-1 and T2G mutant substantially inhibited STS-
induced changes in the expression of Bcl-2 and Bcl-xL and
Bax, preserving the ratios of Bax/Bcl-2 and Bax/Bcl-xL levels
at basal control levels (Figures 6a–c). A direct indication of
MMP-independent neuroprotection by TIMP-1 was observed
as there was no detectable difference between the expres-
sion of these proteins in TIMP-1 and T2G mutant treated
cells; however, TIMP-2 did not show this effect. As expected,
BDNF increased the expression of Bcl-2, Bcl-xL and
decreased the expression of Bax and also preserved the
basal control ratios.
22 Taken together, these results suggest
TIMP-1 increases the expression of anti-apoptotic proteins in
neurons challenged with cytotoxic stimuli and also inhibits
the expression of pro-apoptotic proteins, which protects
neurons from mPTP opening and shifts the fate of neurons
from apoptosis toward pro-survival pathways. Further, this
activity is TIMP-1 speciﬁc and mediated by regulation of
mPTP opening, independent of MMP-inhibition, suggesting a
direct effect modulating the cell fate by regulating initiation of
apoptosis.
Discussion
Neuroinﬂammation induced because of chronic HIV-1 infec-
tion in the CNS is an intense topic of investigation in order to
both expand the mechanistic framework of the underlying
pathophysiology and to characterize potential targets for
further therapeutic interventions. In this regard, the current
investigations have characterized that the initial TIMP-1
upregulationinreactiveastrocytesduringHIV-1CNSinfection
is a protective mechanism against HIV-1-associated neuro-
toxicity.Thus,lossofTIMP-1duringchronicinﬂammationmay
not only exacerbate ECM breakdown due to lack of MMP
inhibition,butalsoleadtolossofdirectneuroprotectiveeffects
mediated by TIMP-1.
Our studies, for the ﬁrst time, identiﬁed the neuroprotective
potential of TIMP-1 in cultured primary human neurons from
toxicity induced by both HIV-1ADA and cytotoxins such as
STS. Our investigations demonstrated that the anti-apoptotic
property of TIMP-1 is direct, speciﬁc and independent of its
MMP-inhibition abilities. The exogenous supply of recombi-
nant human TIMP-1 not only increased the cell viability, but
also preserved the cell morphology following cytotoxic
treatments of STS or HIV-1ADA. Further, TIMP-1 modulates
the expression of Bcl-2 family of proteins and inhibits mPTP
opening, which promote neuronal cell survival pathways. It is
noteworthy that neuroprotective effect of TIMP-1, T2G mutant
or BDNF was not only quantitatively but also mechanistically
comparable in the studied parameters.
The MMP activity is tightly regulated through gene expres-
sion and protein secretion, proenzyme activation, sequestra-
tionandinhibitionbytheirendogenousinhibitors,TIMPs.
23An
TIMP/MMPimbalanceandECMdegradationareimplicatedin
a variety of neuroinﬂammatory diseases including HAD.
8
Together, TIMP-1 and -2 possess the potential to inhibit the
activities of all known MMPs (although TIMP-1 is a poor
inhibitor of MMP-14, 16, -19 and -24) and have an essential
role in maintaining the balance between ECM formation and
degradation.
8 Interestingly, TIMP-1 and -2 levels increase in
many neurodegenerative disorders, including Alzheimer’s
Figure 4 TIMP-1 mediates neuroprotection against HAD-relevant HIV-1 virus.
Human neurons were ﬁxed and assayed with TUNEL assay after treatment with
clariﬁed HIV-1ADA and/or 50ng/ml TIMP-1 for 20h. Panels are representative
micrograph(originalmagniﬁcationX200)overlaysofTUNELandDAPIstainingfrom
control (a), TIMP-1 (b), HIV-1ADA (c) and HIV-1ADAþTIMP-1 (d). Arrows and
arrowheads represent TUNEL-positive or negative cells, respectively. Cell counts
from ﬁve random microscope ﬁelds in each replicate, three replicates per condition
were analyzed as % apoptotic (TUNEL-positive) cells (e). Data is representative of
at least three independent biological replicates and presented as mean±S.E.M.
Symbols centered over the error bar indicate the relative level of the signiﬁcance
compared with untreated control (***Po0.001) or HIV-1ADA-alone (
xxxPo0.001)
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Cell Death and Diseasedisease, Huntington’s disease, Parkinson’s disease, and
amyotrophic lateral sclerosis.
8 We have previously reported
that TIMP-1 is inducible in astrocytes after acute exposure to
IL-1b.
9 Further, TIMP-1 protein levels decrease and MMP-2
and pro-MMP-9 levels increase in the CSF of HAD patients as
compared with non-demented HIV-1 seropositive or serone-
gative controls.
9 The differential regulation of TIMP-1 by glia
during neuroinﬂammation serves multiple purposes. For
example, increased MMP expression can facilitate MP
inﬁltration into the CNS in HAD involving degradation of the
ECM, which can be countered by TIMP-1.
24 Owing to MMP-
inhibition activity, TIMP-1 has a variety of roles, viz. protecting
neurons during severe cerebral ischemia,
25 reducing neurite
length, increasing the size of growth cones,
26 generation
and differentiation of oligodendrocytes
27 and attenuation of
demyelination in experimental autoimmune encephalo-
myelitis (EAE).
4
The adenoviral delivery of TIMP-2 also had a protective
effect in cerebral ischemia due to MMP-inhibition activity.
28
TIMP-1 protects rat hippocampal neuronal death in culture
against glutamate-induced excitotoxicity.
11 Our results show
the neuroprotective potential of TIMP-1 and demonstrate its
role in protection from HIV-1-induced neurotoxicity for the ﬁrst
time. Additionally, TIMP-1 also protected human neurons
from a broad-spectrum cytotoxin, STS. There are indications
thatTIMP-1 is implicated in diverse neuroprotection pathways
during various neuronal injuries, viz. inﬂammatory, (EAE
model),
4 excitoxicity (glutamate dysregulation),
11 and neuro-
nal activity-dependent injuries (kainate-seizure mouse
model).
5 TIMP-1 has also been linked to ECM preservation
through MMP-inhibition, non-inhibiting MMP-regulation and
through the non-classical modulation of ionotropic glutamate
receptors.
5,11,29 Studies with potassium cyanide and TIMP-1
knockout also indicate that TIMP-1-mediated neuroprotection
may not be evident in all types of neuronal injuries.
5,11 Thus,
TIMP-1 has differential effects on neurons depending on the
respective mechanisms of the speciﬁc insults and associated
tissue contexts. Therefore, throughout this study, we included
STS, an apoptosis induction model used extensively in a
variety of cell types, including neurons to study neuro-
degeneration and neuroprotection.
30
Our data support that STS induces apoptosis in cultured
primary human neurons. Interestingly, cotreatment with
TIMP-1 or T2G mutant reduced apoptosis, preserved cell
morphology,andincreasedcellviabilityinSTS-treatedhuman
neurons equivalent to a well-known neurotrophic factor
(BDNF). Microglia is the predominant target of HIV-1 infection
in the CNS. Infected microglia produce progeny virus and
cytokines, thereby activating bystander cells via cytokines
and viral toxins. Consequently, HIV-1-induced neuronal
apoptosis may be mediated by both viral- and glial cell-
derived soluble factors including proinﬂammatory cytokines.
Various mechanisms have been demonstrated depending on
the viral proteins, suggesting it is a complex process.
Therefore, it is a novel ﬁnding that TIMP-1 protects neurons
from a broad-spectrum cytotoxin. A better understanding of
TIMP-1-mediated neuroprotection against HIV-1 will be help-
ful in developing new therapeutic strategies.
In addition to the well-described MMP-dependent actions,
recently several studies have demonstrated that TIMPs
perform a number of MMP-independent actions. Importantly,
TIMP-2 promotes neuronal differentiation by inhibiting cell
proliferation in an MMP-independent manner.
31 Using the
T2G mutant of N-TIMP-1, we demonstrate directly that
inhibition of apoptosis of human neurons by TIMP-1 is in fact
mediated independently of its effects on MMP activity. The
dose of T2G used in these experiments (28ng/ml; 2nM) is
slightlyless thanits Ki forMMP-9,
15 a concentration atwhichit
would be expected to only partially (o50%) inhibit MMP-9.
Our data show that TIMP-1-mediated neuroprotection is, at
least in part, MMP-independent and an addition into its non-
classical functions because the T2G mutant was effective as
Figure 5 TheTIMP-1inhibitsthemPTPopeninginducedby HIV-1ADAor STS.Thechangesin mPTPin humanneuronsweremonitoredby Calcein/CoCl2 assay.Calcein
(green ﬂuorescence) colocalized with MitoTraker (red) represents closed mPTP (arrows), while loss of mitochondrial green ﬂuorescence represents opening of mPTP
(arrowheads). Control (a) and TIMP-1 treated neurons (d) show bright calcein ﬂuorescence (green/yellow) indicating intact mitochondria. Neurons treated with STS or HIV-1
display a signiﬁcant decrease in calcein ﬂuorescence suggest opening of mPTP and quenching of calcein ﬂuorescence by cytoplasmic CoCl2 (b and c). Simultaneous
treatment of TIMP-1 signiﬁcantly blocked the decrease in calcein ﬂuorescence caused by STS or HIV-1 suggesting it inhibits opening of mPTP (e and f)
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Cell Death and Diseasewild type TIMP-1; but other MMP-inhibitors, TIMP-2 or -3, did
not protect neurons from STS-induced apoptosis. In contrast
to Tan et al.’s study,
11 where they demonstrated that
TIMP-1-mediated neuroprotection against glutamate is
MMP-dependent; in our STS model, neuroprotection was
independent of MMP-inhibition activity. This seeming dis-
agreementwithourresultsmaybeduetodifferentparadigms,
toxic mechanisms and species used in the two studies. There
are signiﬁcant sequence differences between the rat and
humanTIMP-1mostnotablyinthecrucialN-terminalregion,
15
human is CTCVPPH and rat is CSCAPTH, which has large
effects on speciﬁcity and might reﬂect differences in targets
between the two species. Further, in our study we supplied
TIMP-1exogenouslytoneurons,whichissimilartothenatural
method of TIMP-1 delivery, as compared with transfection of
neurons.
11 We utilized STS and HIV-1ADA to cause cyto-
toxicity. Exactly how MMP-independent effects are mediated
at the molecular level is still to be determined. However,
studies suggest that TIMPs can bind to a variety of cell-
surface receptors, including CD63 for TIMP-1, a3b1 integrin
for TIMP-2 and TIMP-3 to the vascular endothelial growth
factor receptor-2, raising the possibility that TIMPs can
directly signal through these speciﬁc receptors.
6,32,33 Our
study indicates a possible neurotrophic pathway by TIMP-1,
independent of binding, sequestration, or inhibition of MMPs.
It is possible that pro-survival pathways are activated in cells
directly by TIMP-1 without involvement of MMP-binding.
Outer mitochondrial membrane permeability is regulatedby
Bcl-2 family protein expression and the ratio of Bax to Bcl-2.
34
Ourresults demonstratethatTIMP-1attenuatesSTS-induced
neurotoxicity through upregulation of anti-apoptotic proteins,
Bcl-2 and Bcl-xL, and downregulation of the pro-apoptotic
protein, Bax. Data demonstrate that TIMP-1 preserves the
Bax/Bcl-2 and Bax/Bcl-xL ratios at basal control levels.
Further, this effect was direct, independent of MMP-inhibitory
activity and equal to BDNF as the T2G mutant and BDNF had
equivalent effects. Our data demonstrate that STS-induced
neurotoxicityinhumanneuronsinvolveschangesinBax/Bcl-2
or Bax/Bcl-xL ratios and opening of mPTP. Our data show that
TIMP-1inhibitstheopeningofmPTPinducedbyeitherSTSor
HIV-1,andthus,indicatesdirecttrophicsignalingbyTIMP-1in
human neurons.
As TIMP-1 is a small extracellular protein, any potential
signaling is likely to be mediated through a cell-surface
receptor. To activate pro-survival or anti-apoptotic pathways,
TIMP-1 modulates Bcl-2, Bax, andBcl-xL protein levelsduring
neurotrophic factor deprivation and through phosphotidylino-
sitol-3 kinase (PI3K), c-Jun N-terminal kinase, JAK2/PI3K/Akt
pathways as shown in a variety of cell types.
8,20 Interestingly,
TIMP-1 binds to cell surface targets and translocates into the
nucleus.
35,36 Recently, CD63, a tetraspanin,which modulates
signaling by integrin complexes, has been identiﬁed as a cell-
surface interacting partner for TIMP-1 in the non-malignant
breast epithelial cell line, MCF10A.
6 Interestingly, this study
characterized the C-terminal domain of TIMP-1 as the
interaction partner for CD63, whereas the N-TIMP-1 mutant
T2G that lacks the C-terminal domain, was sufﬁcient for
neuroprotectioninourstudy.
6,37Moreover,modulationofanti-
apoptotic proteins by TIMP-1 in human neurons suggests that
different domains of the TIMP-1 protein may mediate several
separate signaling pathways. This appears to indicate that
TIMP-1 neuroprotective signaling can be mediated through
other receptors and/or interaction partners besides CD63
and the net outcome of these signaling pathways confers
Figure 6 TIMP-1 enhances the Bcl-2 and Bcl-xL expression and decreases the
Bax/Bcl-2 and Bax/Bcl-xL ratios in toxin-challenged neurons. Western blot analysis
was performed on whole-cell lysates of primary human neurons challenged with
STS (0.3mM)for 24h, with or without 50ng/mlof TIMP-1, TIMP-2,BDNF, or28ng/ml
T2GfortheexpressionofBcl-2,Bcl-xL,Baxandb-actin.Densitometricanalysiswas
performed and protein expression relative to b-actin in each treatment is presented
on top of each band (a). The fate of cell survival/apoptosis is presented by ratios of
Bax/Bcl-2 and Bax/Bcl-xL (b and c). Symbols centered over the error bar indicate
the relative level of the signiﬁcance compared with untreated control (***Po0.001)
or STS-alone (
xxxPo0.001)
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apoptotic or growth promoting pathways activated or modu-
lated by TIMP-1 indicates mechanisms not classically
mediated through MMPs.
In summary, TIMP-1 expression by glial cells is neuropro-
tective against general neurotoxicity, exogenous HIV-1 and
possibly from neuroinﬂammation or neurodegenerative dis-
eases. Moreover, our results indicate that TIMP-1-neuropro-
tection could be mediated through a neurotrophic pathway
without the involvement of MMPs. We also demonstrate that
TIMP-1 modulates the anti-apoptotic/pro-survival pathwaysin
human neurons. Therefore, we propose that the TIMP-1
protein is a neuroprotective signal to neurons. In this regard,
the measurement of TIMP-1 level in the CSF of CNS disease
patients could be a novel prognostic tool to predict the
pathological outcome, while careful immune-modulation to
manipulate TIMP-1 levels may slow or reverse neuronal
damage in CNS diseases and injuries. Furthermore, inter-
ventions to restore or supplement TIMP-1 during the early
stages of neuronal inﬂammation may signiﬁcantly decrease
the severity of neurotoxicity, tissue damage and associated
degenerative symptoms. Bearing in mind the broad range of
signaling activities of TIMP-1 in other cell types, it would be
important to dissect the precise signaling pathways modu-
lated by TIMP-1 that affect neuron viability before implemen-
tationofTIMP-1-deliverytherapyforCNSneurodegeneration.
Materials and Methods
Primary human neuron cultures and treatments. Human fetal
neurons were isolated and cultured from ﬁrst and early second trimester elective
aborted specimens obtained from the Birth Defects Laboratory, University of
Washington (Seattle, WA, USA) as previously described.
38 The procedure was
followed in full compliance with the ethical guidelines of the National Institutes of
Health (NIH), Bethesda, MD, USA; the University of Washington, the University of
Nebraska, Omaha, NE, USA; and North Texas Health Science Center, Fort Worth,
TX, USA. The neurons were seeded at density of 0.1 10
6cells/cm
2 in poly-D-
lysine coated 48-well plates. Neuronal cultures were assessed after 2 weeks by
immunostaining with antibodies to neuronal marker, MAP-2 (Millipore, Billerica,
MA, USA) and astrocyte marker, glial ﬁbrillary acidic protein (GFAP, Dako North
America, Inc., Carpinteria, CA, USA). The culture enriched with 490% neurons
were utilized in neurotoxicity/neuroprotection experiments. STS (Merck, KGaA,
Darmstadt, Germany) or HIV-1 was added with and without following proteins:
TIMP-1, -2, -3, BDNF (R&D Systems, Minneapolis, MN, USA) or T2G mutant. In
experiments utilizing both TIMP-1 and T2G, the differences in molecular weights of
whole TIMP-1 protein and the N-terminal domain of TIMP-1 were taken into
consideration; therefore, 28ng/ml of T2G was used alongside of 50ng/ml TIMP-1
to provide the same molar concentration of proteins.
Neurotoxicity/protection assays. Various cell viability, apoptosis detec-
tion and quantitation assays were used. MTT assay, a colorimetric assay for
metabolic activity measurement was performed for cell viability as described
previously.
39 DNA fragmentation was assayed using the dsDNA ELISA (Roche
Diagnostics, Indianapolis, IN, USA) according to the manufacturer’s directions.
Apoptotic cells were visualized using the TUNEL assay, using In Situ Cell Death
Detection Kit according to the manufacturer’s directions (Roche), and counter-
stained with DAPI (Life Technologies). Trypan-blue exclusion assay was
performed using 0.2% trypan-blue in hank’s buffered salt solution (HBSS, Life
Technologies) on cells for 15min to observe cell membrane integrity. Live cells
exclude trypan-blue staining; however, dye traverses the membrane in dead cells
giving a distinctive blue color. In TUNEL assay and trypan-blue exclusion assay,
microscope images were taken on an Eclipse TE-300 inverted microscope (Nikon
Instruments Inc., Melville, NY, USA). For each experimental condition, a total of
ﬁve to ten random ﬁelds from multiple replicates were taken at magniﬁcation X200.
Microscopic images presented in this paper show representative data from at least
three independent donors per experiment. Cells in microscope images were
quantiﬁed as number of stained cells/total number of cells. Each micrograph
contained an average of 200 cells.
mPTP assay. Opening of mPTP in cultured primary human neurons treated
with STS (0.3mM) or HIV-1ADA with or without TIMP-1 was assessed by calcein/
Co
2þ-quenching technique as described by using the MitoProbe Transition Pore
Assay Kit (Life Technologies) according to the manufacturer’s instructions.
40
Brieﬂy, cells were loaded with 1mM calcein-AM (green) 1mM Hoechst (blue), 2mM
CoCl2 and 20nM MitoTracker Red (Life Technologies) at 37
oC for 15–20min in
phenol red free HBSS having 1.26mM Ca
2þ and 0.5mM Mg
2þ supplemented
with 10mM glutamine, 10mM HEPES (Life Technologies). After washings, live cells
were imaged using Nikon Eclipse TE-300 microscope with appropriate excitation
and emission ﬁlters for ﬂuorescein. The change in green ﬂuorescence intensity
and from green/yellow to red indicates mPTP opening. CoCl2 quenched all
ﬂuorescence outside the mitochondria, which facilitates the elucidation of the
subtle phenomena associated with mitochondrial permeability transition leading to
programmed cell death.
Immunoblot analysis. Primary human neurons were cultured as adherent
monolayers in 25 cm
2 ﬂasks at a density of 2.5 10
6cells per ﬂask. The following
day, cells were treated with 0.3mM STS with/without 50ng/ml BDNF, TIMP-1, TIMP-2
(50ng/ml each, R&D Systems) or 28ng/ml T2G mutant. Whole-cell lysates were
prepared after 24h, resolved by 12% sodium dodecyl sulfate polyacrylamide gel
electrophoresis and subsequently transferred to a nitrocellulose membrane using
i-Blot (Life Technologies). The membrane was blocked with 5% BSA (Sigma,
St. Louis, MO, USA) in PBST (phosphate-buffered saline, pH7.4, 0.1% Tween-20) for
1h before hybridizing with anti-b-actin (1:5000, Santa Cruz Biotechnology, Santa
Cruz, CA, USA), anti-Bcl-2 (1:250), anti-Bcl-xL (1:250) or anti-Bax (1:200, all from
Abcam, Cambridge, MA, USA) and thereafter, in species-speciﬁc secondary
antibodies (1:5000). The western blot was visualized and band intensities were
quantiﬁed by densitometry analysis (Proteinsimple, Santa Clara, CA, USA).
Statistical analysis. All quantitative assays were analyzed using Prism 5.0
(GraphPad software, La Jolla, CA, USA) with one-way analysis of variance
followed by Newman-Keuls multiple comparisons post-tests. Signiﬁcance level
was set at Po0.05. All experiments are expressed as mean±S.E.M. of triplicates
and are representative of a minimum of three independent donors.
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